BIOTRONIK Announces Treatment of First Patient with Unique Bioabsorbable Magnesium DREAMS Scaffold
Vascular Intervention / Clinical evaluation of the latest generation of bioabsorbable magnesium scaffold for the treatment of vascular disease has begun
DREAMS is a bioabsorbable scaffold that combines the superior mechanical advantages of a metallic stent with a reliable bioabsorption profile that serves to open vessels and keep them from re-clogging while avoiding the long-term disadvantages of permanent metal stents. Permanent stents cage the vessel segment over the course of the patient's life. In contrast, this device - made of a bioabsorbable magnesium alloy, which is coated with a bioabsorbable polymer matrix and an anti-proliferative Limus drug - is designed to be absorbed over time, leaving a naturally restored vessel.
Building on the results of the BIOSOLVE-I study, which gave BIOTRONIK valuable insight into the clinical workings of the first generation of DREAMS, BIOSOLVE-II is a prospective, multi-center clinical trial evaluating the safety and efficacy of DREAMS in its improved design. Approximately 120 patients are expected to be enrolled, with follow-up investigations performed at 1, 6, 12, 24, and 36 months. The primary endpoint is in-segment late lumen loss (LLL). This study will be used for regulatory approval of the device.
"I was impressed by the ease of deliverability and vessel adaptability," commented Prof. Haude after successful implantation of the first DREAMS scaffold. "Even in quite a challenging lesion like this with significant calcification, the acute performance was similar to a contemporary drug-eluting stent, but offering the advantage of uncaging the vessel in the long run."
"As a global pioneer in bioabsorbable magnesium, BIOTRONIK has refined this technology based on physicians' input to deliver the optimal balance between vessel scaffolding, absorption profile, and drug elution characteristics," commented Dr. Daniel Buehler, President BIOTRONIK Vascular Intervention. "With the promising clinical data of our first generation in the BIOSOLVE-I study, and the preclinical data of this new generation, I am confident that this groundbreaking treatment will prove its efficacy."
The BIOSOLVE-II study will enroll patients in Germany, Belgium, Denmark, The Netherlands, Switzerland, Spain, Brazil, and Singapore.
As one of the world's leading manufacturers of cardio- and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5600 employees. Several million heart patients around the world have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including BIOTRONIK Home Monitoring® in 2000, the world's first 4F compatible 200mm peripheral stent in 2010, Orsiro, the industry's first hybrid drug-eluting stent in 2011, and the world's first implantable cardioverter-defibrillators and heart failure therapy devices with ProMRI® technology in 2012. This year BIOTRONIK celebrates its 50th anniversary.
For more information, visit: www.biotronik.com
You might also be interested in
- 03.05.2016 - Heart Rhythm 2016: BIOTRONIK Provides a Forum for Physicians to Discuss the Importance of Extending Care Beyond the Implant
- 03.05.2016 - BIOTRONIK Announces FDA Approval of MR Conditional Cardiac Resynchronization Defibrillators
- 20.04.2016 - BIOTRONIK ICD Lead Data from Long-Term Registries Published by Journal of Cardiovascular Electrophysiology